- Home
- INVE vs RLMD Comparison
INVE vs RLMD Comparison
Compare INVE & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- RLMD
- Stock Information
- Founded
- INVE 1990
- RLMD 2004
- Country
- INVE United States
- RLMD United States
- Employees
- INVE N/A
- RLMD N/A
- Industry
- INVE Computer peripheral equipment
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- RLMD Health Care
- Exchange
- INVE Nasdaq
- RLMD Nasdaq
- Market Cap
- INVE 85.9M
- RLMD 81.3M
- IPO Year
- INVE 1997
- RLMD N/A
- Fundamental
- Price
- INVE $4.00
- RLMD $2.26
- Analyst Decision
- INVE Strong Buy
- RLMD Hold
- Analyst Count
- INVE 2
- RLMD 2
- Target Price
- INVE $5.50
- RLMD $1.00
- AVG Volume (30 Days)
- INVE 33.7K
- RLMD 221.8K
- Earning Date
- INVE 11-06-2025
- RLMD 11-07-2025
- Dividend Yield
- INVE N/A
- RLMD N/A
- EPS Growth
- INVE N/A
- RLMD N/A
- EPS
- INVE 3.12
- RLMD N/A
- Revenue
- INVE $23,538,000.00
- RLMD N/A
- Revenue This Year
- INVE N/A
- RLMD N/A
- Revenue Next Year
- INVE $9.06
- RLMD N/A
- P/E Ratio
- INVE $1.28
- RLMD N/A
- Revenue Growth
- INVE N/A
- RLMD N/A
- 52 Week Low
- INVE $2.86
- RLMD $0.24
- 52 Week High
- INVE $4.29
- RLMD $3.67
- Technical
- Relative Strength Index (RSI)
- INVE 58.34
- RLMD 56.72
- Support Level
- INVE $3.78
- RLMD $1.98
- Resistance Level
- INVE $4.07
- RLMD $2.63
- Average True Range (ATR)
- INVE 0.20
- RLMD 0.20
- MACD
- INVE 0.02
- RLMD -0.01
- Stochastic Oscillator
- INVE 89.65
- RLMD 55.24
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.